Evidence map›Paper›PMID 35133792›Full record

ArticleACS infectious diseases2022

Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.

Rui Wang, Jiahui Chen, Yuta Hozumi, Changchuan Yin, Guo-Wei Wei

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Local Anaesthetic Procaine Prodrugs ProcClusterInternational journal of molecular sciences · 2023
    Article
  8. Review
  9. RSC medicinal chemistry · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rui WangDepartment of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States.ORCID 0000-0002-7402-6372
Jiahui ChenDepartment of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States.ORCID 0000-0001-5416-6231
Yuta HozumiDepartment of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States.
Changchuan YinDepartment of Mathematics, Statistics, and Computer Science, University of Illinois at Chicago, Chicago, Illinois 60607, United States.ORCID 0000-0002-4147-4195
Guo-Wei WeiDepartment of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States.ORCID 0000-0002-5781-2937
Michigan State University · USUniversity of Illinois Chicago · US

Funding

AI-based platform for predicting emerging vaccine-escape variants and designing mutation-proof antibodiesR01AI164266 · NIAID · UNIVERSITY OF GEORGIA · PI Guowei Wei, YONG-HUI ZHENG · 2022 to 2026
$2.7M
Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impactsR01GM126189 · NIGMS · MICHIGAN STATE UNIVERSITY · PI WEI, GUOWEI · 2018 to 2021
$1.4M
NIAID NIH HHS R01 AI164266NIGMS NIH HHS R01 GM126189
6 · The paper itself

Abstract

The surge of COVID-19 infections has been fueled by new SARS-CoV-2 variants, namely Alpha, Beta, Gamma, Delta, and so forth. The molecular mechanism underlying such surge is elusive due to the existence of 28 554 unique mutations, including 4 653 non-degenerate mutations on the spike protein. Understanding the molecular mechanism of SARS-CoV-2 transmission and evolution is a prerequisite to foresee the trend of emerging vaccine-breakthrough variants and the design of mutation-proof vaccines and monoclonal antibodies. We integrate the genotyping of 1 489 884 SARS-CoV-2 genomes, a library of 130 human antibodies, tens of thousands of mutational data, topological data analysis, and deep learning to reveal SARS-CoV-2 evolution mechanism and forecast emerging vaccine-breakthrough variants. We show that prevailing variants can be quantitatively explained by infectivity-strengthening and vaccine-escape (co-)mutations on the spike protein RBD due to natural selection and/or vaccination-induced evolutionary pressure. We illustrate that infectivity strengthening mutations were the main mechanism for viral evolution, while vaccine-escape mutations become a dominating viral evolutionary mechanism among highly vaccinated populations. We demonstrate that Lambda is as infectious as Delta but is more vaccine-resistant. We analyze emerging vaccine-breakthrough comutations in highly vaccinated countries, including the United Kingdom, the United States, Denmark, and so forth. Finally, we identify sets of comutations that have a high likelihood of massive growth: [A411S, L452R, T478K], [L452R, T478K, N501Y], [V401L, L452R, T478K], [K417N, L452R, T478K], [L452R, T478K, E484K, N501Y], and [P384L, K417N, E484K, N501Y]. We predict they can escape existing vaccines. We foresee an urgent need to develop new virus combating strategies.

Indexed as

comutationsCOVID-19infectivitySARS-CoV-2vaccine-breakthroughvaccine-resistant

Identifiers

PMID35133792
PMCPMC8848511
OpenAlexW4211023215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.